Quantcast
Last updated on April 24, 2014 at 17:35 EDT

Latest Quark Pharmaceuticals Stories

2014-03-19 00:22:17

TOKYO, March 19, 2014 /PRNewswire/ -- Astellas Pharma Inc. ("Astellas"; Tokyo: 4503; President and CEO: Yoshihiko Hatanaka) and Daiichi Sankyo Company, Limited ("Daiichi Sankyo," President and CEO: Joji Nakayama) today announced the companies would form a compound library sharing partnership for approximately 400,000 selected compounds. The collaboration enables each party to promote innovative new medicine research and development. This is the first time that a compound library...

2013-10-24 23:20:33

Reportbuyer.com just published a new market research report: Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H2, 2013. London (PRWEB) October 24, 2013 Summary GlobalData's clinical trial report, “Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H2, 2013" provides data on the Acute Renal Failure (ARF) (Acute Kidney Injury) clinical trial scenario. This report provides elemental information and data relating to the...

2012-09-24 22:20:33

LONDON, September 25, 2012 /PRNewswire/ -- Silence Therapeutics Plc (AIM: SLN), a leading international RNAi therapeutics company, today provides a corporate update and announces its interim results for the six months ended 30 June 2012. Ali Mortazavi, Director of Corporate Strategy, said: "These results, including the writedown of our Intradigm investment, mark the end of a very difficult period for Silence Therapeutics. However, post this period, the Company has been...

2012-06-06 02:25:13

LONDON, June 6, 2012 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), a leading global RNA interference [http://silence-therapeutics.com/platform-technologies/rna-interference ] (RNAi) therapeutics company, on Monday presented the latest data from its ongoing Phase I study of Atu027, its lead internal therapeutics candidate, alongside the 2012 American Society of Clinical Oncology ("ASCO") Annual Meeting in Chicago, Illinois. At this...

2012-05-16 22:20:49

LONDON, May 17, 2012 /PRNewswire/ -- - Atu027, a First in Class RNAi Therapy, Demonstrates Potential - Antitumour Activity in Cancer Patients and Possible Biomarker Identified Silence Therapeutics to Announce New Data from Phase I Study of Atu027 in Solid Tumours At 2012 ASCO Annual Meeting Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), a leading global RNA interference (RNAi) therapeutics...

2012-03-20 22:20:51

LONDON, March 21, 2012 /PRNewswire/ -- Silence Therapeutics Plc [http://silence-therapeutics.com ] (AIM: SLN), a leading international RNAi therapeutics company [http://silence-therapeutics.com/pipeline/clinical-programs/#!/about-us ], today announces its unaudited preliminary results for the year ended 31 December 2011. HIGHLIGHTS - Impressive interim data from Phase I trials of Atu027 (lead programme in metastatic cancer) presented at the...

2012-03-09 09:20:00

LONDON, March 9, 2012 /PRNewswire/ -- Silence Therapeutics plc [http://silence-therapeutics.com ] (AIM: SLN) ("Silence" or "the Company"), a leading RNA [http://silence-therapeutics.com/content/therapeuticplatform/overview.htm ] interference (RNAi) therapeutics company, responds to comments that the Tuschl I (EP 1309726) patent has been upheld in European Opposition Proceedings without any modification. Concluding on 1 March 2012, the European Patent Office held oral opposition...

2012-02-10 01:00:00

LONDON, February 10, 2012 /PRNewswire/ -- -- Tony Sedgwick steps up to Chief Executive Officer from Chief Business Officer -- -- Thomas Christely resigns as a Director of the Company -- Silence Therapeutics plc [http://silence-therapeutics.com ] (AIM: SLN) ("Silence" or "the Company"), a leading RNA [http://silence-therapeutics.com/content/therapeuticplatform/overview.htm ] interference (RNAi)...

2012-01-06 01:00:00

LONDON, January 6, 2012 /PRNewswire/ -- Silence Therapeutics plc [http://www.silence-therapeutics.com ] (AIM: SLN) ("Silence" or the "Company"), a leading RNA [http://silence-therapeutics.com/content/therapeuticplatform/overview.htm ] interference (RNAi) therapeutics company, announces the successful completion of its research work under the Research Collaboration and Delivery Collaboration with its partner AstraZeneca and its biologics arm, MedImmune. The first collaboration...

2012-01-04 07:00:00

FREMONT, Calif., Jan. 4, 2012 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced interim results from the first two cohorts of its Open Label, first-in-human Phase I clinical study of QPI-1007, the Company's proprietary synthetic siRNA drug candidate for ocular neuroprotection, in patients with recent onset of non-arteritic anterior ischemic optic neuropathy (NAION). QPI-1007 exhibited no dose...